KRAS and colorectal carcinoma: To investigate mechanisms of KRAS-associated cetuximab (CET) resistance, we used an established cell culture model of acquired CET resistance consisting of isogenic CET sensitive and resistant Lim1215 and DiFi colorectal cancer (CRC) cell lines (Misale et al. 2012).